Neuphoria Therapeutics (NEUP) Operating Leases (2020 - 2025)

Neuphoria Therapeutics (NEUP) has 6 years of Operating Leases data on file, last reported at $19322.0 in Q1 2025.

• Quarterly Operating Leases changed N/A year-over-year to $19322.0 in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $19322.0 (changed N/A YoY) and the FY2024 annual result came in at $117628.0, down 50.95% from the prior year.
• Operating Leases eased to $19322.0 in Q1 2025 per NEUP's latest filing, from $49818.0 in the prior quarter.
• Across five years, Operating Leases topped out at $534128.0 in Q2 2021 and bottomed at $19322.0 in Q1 2025.
• The 5-year median for Operating Leases is $179701.0 (2023), against an average of $235253.2.
• The widest annual swing landed in 2021, when Operating Leases surged 3103.76%; it then tumbled 51.35% in 2024.
• Tracing NEUP's Operating Leases over 5 years: stood at $447697.9 in 2021, then declined by 14.63% to $382188.6 in 2022, then sank by 36.74% to $241774.0 in 2023, then tumbled by 79.39% to $49818.0 in 2024, then plunged by 61.21% to $19322.0 in 2025.
• Per Business Quant, the three latest NEUP Operating Leases figures stand at $19322.0 (Q1 2025), $49818.0 (Q4 2024), and $89469.0 (Q3 2024).

Peer Comparison